NVTA - Invitae Corporation

NYSE - Nasdaq Real Time Price. Currency in USD
19.39
-0.23 (-1.17%)
As of 3:23PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close19.62
Open19.62
Bid19.33 x 1000
Ask19.35 x 800
Day's Range19.22 - 19.90
52 Week Range9.04 - 28.75
Volume729,292
Avg. Volume2,129,618
Market Cap1.9B
Beta (3Y Monthly)2.45
PE Ratio (TTM)N/A
EPS (TTM)-2.29
Earnings DateNov 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.17
  • Invitae to Participate in the 31st Annual Piper Jaffray Healthcare Conference
    PR Newswire

    Invitae to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    SAN FRANCISCO , Nov. 21, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Shelly Guyer , chief financial officer of Invitae, will participate ...

  • Invitae Launches Invitae Discover Research Platform on Apple Watch; First Study on Platform Will Investigate Genetic Causes of Cardiovascular Disease
    PR Newswire

    Invitae Launches Invitae Discover Research Platform on Apple Watch; First Study on Platform Will Investigate Genetic Causes of Cardiovascular Disease

    PHILADELPHIA, Nov. 15, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced Invitae Discover, a clinical research platform that leverages biometric data available through Apple Watch to provide better understanding of the genetic causes of disease. The first study on the platform will evaluate genetics in cardiovascular disease and was announced in conjunction with the American Heart Association's Scientific Sessions where researchers are presenting data on genetic screening in familial hypercholesterolemia.

  • The Funded: Two hefty rounds lead $800M in Bay Area startup funding at midweek
    American City Business Journals

    The Funded: Two hefty rounds lead $800M in Bay Area startup funding at midweek

    The two big rounds were a $400 million round for a Chinese Tesla competitor whose U.S. operations are in Mountain View and a $100 million round for San Francisco-based food delivery unicorn DoorDash.

  • Thomson Reuters StreetEvents

    Edited Transcript of NVTA earnings conference call or presentation 6-Nov-19 9:30pm GMT

    Q3 2019 Invitae Corp Earnings Call

  • This simple acquisition shows how genetic testing is consolidating, cozying up to doctors and patients
    American City Business Journals

    This simple acquisition shows how genetic testing is consolidating, cozying up to doctors and patients

    Invitae's third acquisition in four months is indicative of consolidation in the genetic testing arena.

  • Invitae to Acquire Clear Genetics
    PR Newswire

    Invitae to Acquire Clear Genetics

    SAN FRANCISCO, Nov. 11, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Clear Genetics, a leading developer of software for providing genetic services at scale. Using intuitive chatbots, Clear Genetics equips patients with actionable information throughout the genetic testing process and provides guidance for understanding test results. The acquisition will further expand Invitae's ability to scale and deliver genetic information as a part of routine medical care.

  • PR Newswire

    University of Vermont Health Network begins offering Genomic DNA Testing

    BURLINGTON, Vt., Nov. 8, 2019 /PRNewswire/ -- The University of Vermont Health Network has begun a pilot project to offer Genomic DNA Testing to patients as part of their clinical care. The pilot program is the beginning of an effort to increase the integration of genetic disease risks into routine medical care, which holds promise for providing Vermonters with valuable information to guide their health decisions. "Our overall health and longevity are determined about 30 percent by genetics," said Debra Leonard, MD, PhD, Chair, Pathology and Laboratory Medicine.

  • ETF Trends

    The Unloved Biotechnology ETF Rally

    Biotechnology stocks have been outperforming over the past month, but ETF investors seem disinterested and are even trimming exposure to this sector. In a weekly update on the flow of money in and out of stock funds, PiperJaffray analyst Christopher J. Raymond pointed out that investors pulled a net $99 million out of healthcare and biotech-related funds in the one-week period ended on Wednesday, Barron's reports. The latest redemptions seems surprising given the recent outperformance of the biotechnology sector.

  • Stocks Take a Rest from Setting All-Time Highs
    Zacks

    Stocks Take a Rest from Setting All-Time Highs

    Stocks Take a Rest from Setting All-Time Highs

  • Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates

    Invitae (NVTA) delivered earnings and revenue surprises of -32.69% and 2.75%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Invitae Reports $56.5 Million in Quarterly Revenue Driven by 129,000 Samples
    PR Newswire

    Invitae Reports $56.5 Million in Quarterly Revenue Driven by 129,000 Samples

    -- Increased quarterly revenue by 51% and volume by 65% year-over-year -- -- Now in network with Cigna, all major payers with approximately 295 million covered lives -- -- Hosting conference call and webcast ...

  • Invitae Highlights Importance of Medical Genetics, Honors Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 38th Annual Conference
    PR Newswire

    Invitae Highlights Importance of Medical Genetics, Honors Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 38th Annual Conference

    SALT LAKE CITY , Nov. 5, 2019 /PRNewswire/ -- Researchers from   Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting research this week at the National Society of Genetic ...

  • Will Genetic Testing Drive Invitae's (NVTA) Q3 Earnings?
    Zacks

    Will Genetic Testing Drive Invitae's (NVTA) Q3 Earnings?

    Several bio-pharma partnerships and acquisitions are likely to have contributed to Invitae's (NVTA) top line in Q3.

  • 8 Undervalued Biotech Stocks to Watch Now
    Investopedia

    8 Undervalued Biotech Stocks to Watch Now

    As investors shift out of growth names and to more defensive pockets of the market, market watchers now see these biotech players as undervalued.

  • Earnings Preview: Invitae (NVTA) Q3 Earnings Expected to Decline
    Zacks

    Earnings Preview: Invitae (NVTA) Q3 Earnings Expected to Decline

    Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is InVitae Corporation (NVTA) A Good Stock To Buy?
    Insider Monkey

    Is InVitae Corporation (NVTA) A Good Stock To Buy?

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

  • Invitae to announce third quarter 2019 financial results on November 6, 2019
    PR Newswire

    Invitae to announce third quarter 2019 financial results on November 6, 2019

    SAN FRANCISCO, Oct. 23, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 9085356.

  • Benzinga

    InVitae Shares Bounce Back Following Analyst Rebuttal To Short Seller Allegations

    On Oct. 11, a short seller article published on Seeking Alpha accused InVitae of being the next Theranos. The short seller implied InVitae’s strong revenue growth may have been obtained via fraudulent measures and InVitae is burning through cash at an irresponsible level. On Oct. 13, Capital Markets Laboratories CEO Ophir Gottlieb published a rebuttal to the Seeking Alpha story.

  • Research presented by Invitae at the American Society of Human Genetics Meeting Pushes Science and Practice of Genetics Forward
    PR Newswire

    Research presented by Invitae at the American Society of Human Genetics Meeting Pushes Science and Practice of Genetics Forward

    -- Advances in classification, new approaches to genetics in cancer and implications of primary and secondary findings for clinical care among wide-ranging data presentations -- HOUSTON , Oct. 17, 2019 ...

  • Zacks

    Rough Start to Fourth Quarter

    Rough Start to Fourth Quarter

  • Does Invitae Corporation's (NYSE:NVTA) CEO Pay Matter?
    Simply Wall St.

    Does Invitae Corporation's (NYSE:NVTA) CEO Pay Matter?

    In 2017 Sean George was appointed CEO of Invitae Corporation (NYSE:NVTA). This report will, first, examine the CEO...

  • Thomson Reuters StreetEvents

    Edited Transcript of NVTA earnings conference call or presentation 6-Aug-19 8:30pm GMT

    Q2 2019 Invitae Corp Earnings Call

  • 5 Top Stock Trades for Thursday: NVDA, MTCH, NVTA
    InvestorPlace

    5 Top Stock Trades for Thursday: NVDA, MTCH, NVTA

    After dropping notably in the morning, stocks reversed and closed higher on the day. It leaves investors wondering what's next for the market. In the meantime, here are a few top stock trades. Top Stock Trades for Tomorrow 1: NvidiaNvidia (NASDAQ:NVDA) stock held the $172.50 level for four consecutive sessions. It was an impressive couple of days as bulls refused to break. On Wednesday, shares caught a boost after Goldman Sachs analysts took their price target from $179 to $192. InvestorPlace - Stock Market News, Stock Advice & Trading TipsAs shares reclaim the 20-day moving average, traders are shifting their outlook higher in the short term. Look to see if the stock can get back to $185, recent resistance earlier this month. Above it puts the high at $188.40 on the table, which comes into play near the 61.8% retracement. On the downside, watch $172.50. Below could send shares to the 50-day and possibly the 200-day moving average. Top Stock Trades for Tomorrow 2: Match GroupMatch Group (NASDAQ:MTCH) took a hit on Wednesday, as cracks start to show up on the chart. For now, shares are holding onto the 61.8% retracement. Below it will put Wednesday's lows on the table. The $65 level has been decent support, while the 200-day moving average is near $64 and the 50% retracement is near $63. On a rebound, see if MTCH stock can get back to $80. Top Stock Trades for Tomorrow 3: InvitaeI love Invitae (NASDAQ:NVTA) for the long term, but it would be foolish to ignore the charts. Invitae is taking out this month's low and falling below the 200-day moving average.Should shares continue lower, look for the 50% retracement just below $19. If it fails as support, look for a potential test of the May lows, with support in the low-$17s. At that point though, bulls may as well just ask for a January gap-fill and test of the 38.2% near $16.50. On the upside, NVTA needs too reclaim the 200-day moving average, as well as the $22 level, which is acting as short-term resistance. Top Stock Trades for Tomorrow 4: CintasCintas (NASDAQ:CTAS) has seen a widening range (blue lines) since popping higher in July. On Wednesday, shares jumped on better-than-expected earnings results. Thanks to its rally, CTAS is reclaiming the 50-day moving average and is approaching resistance at $270. Over $270 puts the 52-week high of $270.36 on the table, as well as a possible run to $276, which is recent trend resistance. Top Stock Trades for Tomorrow 5: ServiceNowServiceNow (NASDAQ:NOW) has been frustrating investors lately, but pleasing traders as it bounces between $250 range support and $270 range resistance. The setup is simple: traders can go long near $250 support and sell near $270 resistance. If shares break down below support, see if the 200-day supports it, along with the 61.8% retracement near $243.75. Over $270 -- which is also roughly the 78.6% retracement -- and a move toward $290 may be under way. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long NVTA and NVDA. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 High-Yield Dividend Stocks Set for Growth * 10 Wonderful Companies Whose Valuations Aren't Quite Fair * 5 Stocks to Buy That Could Double in 2020 The post 5 Top Stock Trades for Thursday: NVDA, MTCH, NVTA appeared first on InvestorPlace.

  • Invitae (NVTA) Dips More Than Broader Markets: What You Should Know
    Zacks

    Invitae (NVTA) Dips More Than Broader Markets: What You Should Know

    In the latest trading session, Invitae (NVTA) closed at $21.68, marking a -1% move from the previous day.

  • Invitae Expands Detect Program to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients
    PR Newswire

    Invitae Expands Detect Program to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients

    SAN FRANCISCO, Sept. 9, 2019 /PRNewswire/ -- Invitae (NVTA), a leading medical genetics company, today announced the availability of Detect Hereditary Pancreatic Cancer, a testing program that offers no-charge genetic testing and counseling to patients with pancreatic cancer. Genetic testing is recommended by clinicians for all pancreatic cancer patients to guide treatment choices and evaluate eligibility for clinical trials.